The Canadian Venous Thromboembolism Research Network is a pan-Canadian, patient-oriented research network dedicated to VTE.
Joined January 2016
- Tweets3.2K
- Following948
- Followers1.8K
- Likes2.2K
CanVECTOR Network retweeted
🌍 Happy belated World Thrombosis Day! 🇨🇦 Ottawa’s sign marks the occasion tonight! 📸 A day late, but thrombosis awareness matters EVERY day, not only October 13! ❤️💙
@ThrombosisCan @CanVECTOR @ISTH @ThrombosisDay #WorldThrombosisDay
CanVECTOR Network retweeted
🔎 Can thromboprophylaxis prevent catheter-related VTE in cancer?
💊 TRIM-Line is ongoing!
🇨🇦 500 patients enrolled
🌍 France, Saudi Arabia & Italy sites planned
📄 Rationale & design:
doi.org/10.1055/a-2963-4656
@TH_Journal @canvector @INVENT_VTE
CanVECTOR Network retweeted
A long journey has come to an end. This article brings together what we set out to do, but it also captures the challenges and precious lessons we learned along the way.
jacc.org/doi/10.1016/j.jacc.…
CanVECTOR Network retweeted
What a fantastic evening celebrating the 25th anniversary of the Adult Thrombosis Fellowship Program at the University of Ottawa during the #ISTH2026 meeting in Paris!
It was wonderful to reconnect with so many former fellows who trained in Ottawa. Thank you to everyone who joined us to celebrate this incredible milestone and to all our fellows.
Looking forward to the next 25 years!
@isth @ThrombosisCan @canvector
CanVECTOR Network retweeted
🎉 Congratulations to Dr. @RodgerMarc and the entire team on their @isth oral presentation! 👏
🤰 An unlikely LEFt score + negative D-dimer safely excluded suspected #DVT in pregnancy without ultrasound.
📊 No VTE events occurred in this low-risk group, while a likely LEFt score identified patients at high risk (≈28% VTE), supporting prompt imaging and close follow-up.
An important step toward safer, evidence-based care for pregnant patients. 👏🔬
#ISTH2026
CanVECTOR Network retweeted
Congratulations to ISTH 2026 Esteemed Career Award Recipients! Drs. Susan Kahn 🇨🇦, Philip Wells 🇨🇦, Michael Lafan, Paolo Prandoni, Maria das Gravas Carvalho. Their accomplishments are exemplary models of research, clinical practice and mentoring excellence. 🥂👏
CanVECTOR Network retweeted
Join us TODAY for the Dragons' Den Competition at #ISTH2026!
Watch 4 investigators pitch their thrombosis studies for a $35,000 CAD prize & network endorsement!
🗳️ Vote for your fav pitch!
🗓️ Today at 12:30 PM 📍 Room S04
bit.ly/4wa1omz
#VTE #Thrombosis #Research
CanVECTOR Network retweeted
🎉 Congratulations to Dr. @sudeeppappur and the entire #EPCATIII team!
A true highlight of #ISTH2026 in Paris: a Late-Breaking Abstract with simultaneous publication in @NEJM.
Practice-changing results showing that aspirin alone after total hip or knee arthroplasty was noninferior to an initial 5-day course of rivaroxaban followed by aspirin for preventing symptomatic VTE, with no clinically meaningful difference in bleeding.
nejm.org/doi/full/10.1056/NE…
@ThrombosisCan @canvector @isth
CanVECTOR Network retweeted
Congrats to @sudeeppappur and the EPCAT-3 team @canvector: *happening now* simultaneous @NEJM publication and presentation at @ISTH2026: Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
CanVECTOR Network retweeted
🎉🩸 We're celebrating 25 years of the Adult Thrombosis Medicine Fellowship at the University of Ottawa!
🌍 Over 90 thrombosis specialists trained from 🇨🇦🇫🇷🇨🇭🇺🇾🇪🇹🇸🇦🇰🇼🇴🇲🇦🇺🇧🇷🇮🇹🇬🇧🇲🇽 and many more.
🗼 During #ISTH2026 in Paris, we'll be hosting a 25th Anniversary Reunion!
🎓 Were you an Ottawa Thrombosis Fellow?
✈️ Will you be at ISTH?
🤝 We'd love to reconnect!
📧 Please contact our Program Director, Dr. @DellucAurelien, if you'd like to join us.
🤖 Made with AI
CanVECTOR Network retweeted
The debate over DOAC selection just got clearer. 🔍
The #COBRRA trial provides a definitive head-to-head look at bleeding risks in #VTE. Tomorrow, we explore the findings!
Join the deep dive with @LanaCastellucci
Register to attend🔗 bit.ly/4thelZT
#Research
CanVECTOR Network retweeted
Susan Kahn is a leading voice in venous thrombosis & its long-term complications. Her work has helped shape patient care and clinical practice globally. Now honored with the 2026 ISTH Esteemed Career Award, she reflects on her career: isth.org/news/news.asp?id=72…
CanVECTOR Network retweeted
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary: nejm.org/doi/full/10.1056/NE…
CanVECTOR Network retweeted
Dans le cadre d’une étude menée par la Dre Lana Castellucci, deux types d’anticoagulants souvent utilisés pour traiter la thromboembolie veineuse ont été comparés. L’un de ces médicaments a pu diminuer de plus de 50 % les cas d’hémorragie.
cihr-irsc.gc.ca/f/54578.html…
ALT Dre Lana Castellucci
CanVECTOR Network retweeted
A study led by Dr. Lana Castellucci compared two types of anticoagulants commonly used to treat venous thromboembolism and showed that one of the medications reduced bleeding by more than 50%.
Learn more: cihr-irsc.gc.ca/e/54578.html…
#BloodClotAwarenessMonth
ALT Dr. Lana Castellucci
CanVECTOR Network retweeted
Groundbreaking research at The Ottawa Hospital ctvnews.ca/ottawa/video/2026…
CanVECTOR Network retweeted
🐍 COBRRA trial finds ↓ clinically relevant bleeding with apixaban vs. rivaroxaban during the first 3 months of treatment for acute VTE (RR 0.46, 95% CI 0.33–0.65)🩸
@uOttawaMed @OttawaHospital @CIHR_IRSC @INVENT_VTE
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: nejm.org/doi/full/10.1056/NE…
CanVECTOR Network retweeted
Ottawa Hospital research finds ‘clear winner’ for safer blood clot treatment ctvnews.ca/ottawa/article/ot…
CanVECTOR Network retweeted
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: nejm.org/doi/full/10.1056/NE…